A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

por Schwartzberg, Lee S., Arena, Francis P., Bienvenu, Bryan J., Kaplan, Edward H., Camacho, Luis H., Campos, Luis T., Waymack, J. Paul, Tagliaferri, Mary A., Chen, Michael M., Li, Dapeng
Publicado 2017

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

por Tannir, Nizar M, Cho, Daniel C, Diab, Adi, Sznol, Mario, Bilen, Mehmet A, Balar, Arjun V, Grignani, Giovanni, Puente, Erika, Tang, Lily, Chien, David, Hoch, Ute, Choudhury, Arkopal, Yu, Danni, Currie, Sue L, Tagliaferri, Mary A, Zalevsky, Jonathan, Siefker-Radtke, Arlene O, Hurwitz, Michael E
Publicado 2022

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

por Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander I., Cho, Daniel C., Guan, Shanhong, Puente, Erika, Nguyen, Tuan, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.
Publicado 2021

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

por Diab, Adi, Gogas, Helen, Sandhu, Shahneen, Long, Georgina V., Ascierto, Paolo A., Larkin, James, Sznol, Mario, Franke, Fabio, Ciuleanu, Tudor E., Pereira, Caio, Muñoz Couselo, Eva, Bronzon Damian, Fernanda, Schenker, Michael, Perfetti, Aldo, Lebbe, Celeste, Quéreux, Gaëlle, Meier, Friedegund, Curti, Brendan D., Rojas, Carlos, Arriaga, Yull, Yang, Haisu, Zhou, Ming, Ravimohan, Shruthi, Statkevich, Paul, Tagliaferri, Mary A., Khushalani, Nikhil I.
Publicado 2023